FDA advisory panel backs compounding pharmacies to produce four popular peptides, defying prior committee advice

The Food and Drug Administration’s advisory panel voted to allow compounding pharmacies to manufacture four peptide drugs that have gained popularity among health‑seeking individuals. The recommendation marks a shift toward broader access to these substances, which are often used off‑label for various wellness claims.

The decision is notable because it runs counter to the recommendations of the Pharmacy Compounding Advisory Committee, highlighting a split between FDA staff and the advisory panel. Critics have suggested the panel’s composition may favor peptide advocates.

If implemented, the ruling could expand the availability of peptide products and signal a more permissive regulatory stance, a development welcomed by proponents of peptide therapies.